terbogrel Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Terbogrel (INN) is an experimental drug that has been studied for its potential to prevent the vasoconstricting and platelet-aggregating action of thromboxanes. Terbogrel is an orally available thromboxane A2 receptor antagonist and a thromboxane A synthase inhibitor. The drug was developed by Boehringer Ingelheim.   Wikipedia

Chemistry

  • SMILES: CC(C)(C)\N=C(/NC#N)\Nc1cccc(c1)\C(=C/CCCC(=O)O)\c2cccnc2
  • InChIKey: XUTLOCQNGLJNSA-RGVLZGJSSA-N
  • Mol. Mass: 405.5
  • ALogP: 4.41
  • ChEMBL Molecule:
    terbogrel  
More Chemistry

Pharmacology

Alternative names

(5e)-6-(m-(3-tert-butyl-2-cyanoguanidino)phenyl)-6-(3-pyridyl)-5-hexenoic acid | 6-(3-(((cyanoamino)((1,1-dimethylethyl)amino)methylene)amino)phenyl)-6-(3-pyridinyl)hexenoic acid | bibv 308 | bibv-308-se | terbogrel

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Healthy Volunteers (Phase 1)

Hypertension, Pulmonary (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue